Eli Lilly and Company (LLY)

NYSE: LLY · IEX Real-Time Price · USD
+0.56 (0.16%)
Mar 31, 2023, 12:42 PM EDT - Market open
Market Cap 325.02B
Revenue (ttm) 28.54B
Net Income (ttm) 6.24B
Shares Out 952.35M
EPS (ttm) 6.90
PE Ratio 49.67
Forward PE 39.06
Dividend $4.07 (1.19%)
Ex-Dividend Date Feb 14, 2023
Volume 778,262
Open 342.00
Previous Close 340.69
Day's Range 340.69 - 343.37
52-Week Range 276.83 - 375.25
Beta 0.35
Analysts Buy
Price Target 388.37 (+13.81%)
Earnings Date Apr 27, 2023

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal... [Read more]

Sector Healthcare
Founded 1876
Employees 35,000
Stock Exchange NYSE
Ticker Symbol LLY
Full Company Profile

Financial Performance

In 2022, LLY's revenue was $28.54 billion, an increase of 0.79% compared to the previous year's $28.32 billion. Earnings were $6.24 billion, an increase of 11.88%.

Financial Statements

Analyst Forecast

According to 30 analysts, the average rating for LLY stock is "Buy." The 12-month stock price forecast is $388.37, which is an increase of 13.81% from the latest price.

Price Target
(13.81% upside)
Analyst Consensus: Buy
Stock Forecasts


Final trades: Intel, JPMorgan, Eli Lilly & Amgen

The final trades of the week. With CNBC's Tyler Mathisen and the Fast Money traders, Steve Grasso, Courtney Garcia, Tim Seymour and Guy Adami.

Other symbols: AMGNINTCJPM
1 day ago - CNBC Television

Drugs for obesity are a massive market, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to discuss obesity drugs with CNBC's Tyler Mathisen and the Fast Money traders.

Other symbols: NVO
1 day ago - CNBC Television

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Other symbols: GSK
4 days ago - Zacks Investment Research

Alzheimer's Blood Test That Could Help Diagnose Disease Earlier Is Being Developed By Eli Lilly And Roche

If approved, the test could streamline the diagnostic journey and help patients get earlier access to future Alzheimer's treatments, Roche said.

Other symbols: RHHBY
1 week ago - Forbes

Eli Lilly Is Priced for Perfection in the Obesity Market

The company has outperformed its pharma peers in recent years, but its valuation leaves little room for error.

1 week ago - WSJ

7 Healthcare Stocks to Buy for Long-Term Growth and Stability

Stock market investors have been on a rollercoaster ride over the past year. The Federal Reserve continues to be hawkish in controlling inflation.

1 week ago - InvestorPlace

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

1 week ago - Zacks Investment Research

Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting

INDIANAPOLIS , March 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for Cancer Research ...

2 weeks ago - PRNewsWire

Eli Lilly suffers setback in Alzheimer's treatment plans

Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the setback Eli Lilly is facing for one of its Alzheimer's treatment drugs while it looks to a phase 3 trial for another drug.

3 weeks ago - Yahoo Finance

Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study

Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.

3 weeks ago - Zacks Investment Research

Eli Lilly Alzheimer's treatment solanezumab failed to slow disease progression

Solanezumab's failure is a blow to efforts to treat Alzheimer's in people who have not yet shown clinical symptoms.

3 weeks ago - CNBC

Lilly's drug aimed at preventing Alzheimer's fails

Eli Lilly & Co. said late Wednesday that a drug aimed at preventing Alzheimer's disease before symptoms start has failed to slow down cognitive decline in healthy older adults at risk of developing th...

3 weeks ago - Market Watch

Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease

Results showed solanezumab did not slow cognitive decline in preclinical Alzheimer's disease or reduce risk of progression to symptomatic Alzheimer's disease Solanezumab targets soluble amyloid beta, ...

3 weeks ago - PRNewsWire

Eli Lilly Drug Fails to Prevent Alzheimer's in Study

The drug, which had failed testing whether it could slow Alzheimer's in people with the disease, was no better than placebo at averting the condition.

3 weeks ago - WSJ

US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes

The application is based on phase III results from the DINAMO trial showing Jardiance® (empagliflozin) tablets significantly reduced A1c (a marker of average blood sugar) versus placebo in participant...

3 weeks ago - PRNewsWire

Eli Lilly's Insulin Decision Puts Others in Hot Seat

The drugmaker's plan moves the spotlight to industry middlemen, who face a barrage of investigations.

3 weeks ago - WSJ

Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer

Eli Lilly (LLY) announces FDA approval of label expansion of Verzenio (abemaciclib), in combination with endocrine therapy, for treating HR+, HER2-, node-positive and high-risk early breast cancer.

3 weeks ago - Zacks Investment Research

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

3 weeks ago - Zacks Investment Research

Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study

The findings, from the COORDINATE-Diabetes trial, demonstrate the benefit of clinic-level educational interventions, including a focus on coordinating care between cardiology and diabetes care provide...

3 weeks ago - PRNewsWire

7 High-Growth Stocks for ESG-Oriented Investors

Generally, a perception exists that supporting environmental, social, and governance ( ESG) initiatives may lead to expansion and profitability erosion, though the enthusiasm toward the following hig...

3 weeks ago - InvestorPlace

Best Buy, Eli Lilly, Salesforce: Stocks That Defined the Week

Here are seven major companies whose stocks moved on the week's news.

Other symbols: BBYCRM
3 weeks ago - WSJ

U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer

High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor  size, and  tumor grade , regardless of Ki-67 score Approval supported by  four-year data from the mo...

3 weeks ago - PRNewsWire

NVS vs. LLY: Which Stock Is the Better Value Option?

NVS vs. LLY: Which Stock Is the Better Value Option?

Other symbols: NVS
3 weeks ago - Zacks Investment Research

Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced a worldwide licensing agreement with Eli Lill...

1 month ago - Business Wire

Biden says other companies will slash insulin prices after Eli Lilly move

U.S. President Joe Biden said on Wednesday that other pharmaceutical companies will have to lower their insulin prices in the wake of Eli Lilly's decision to slash its prices for the popular diabetes ...

1 month ago - Reuters